This differentiation block will not stand, man: ivosidenib for MDS.
作者信息
Beechinor Ryan J, Jonas Brian A
机构信息
Department of Pharmacy, University of California Davis Medical Center, Sacramento, CA.
University of California, San Francisco School of Pharmacy, San Francisco, CA.
出版信息
Blood Adv. 2024 Aug 13;8(15):4207-4208. doi: 10.1182/bloodadvances.2024013427.
Abstract
摘要
相似文献
1
This differentiation block will not stand, man: ivosidenib for MDS.这种分化障碍不会持续下去的，伙计：用于骨髓增生异常综合征的艾伏尼布。
Blood Adv. 2024 Aug 13;8(15):4207-4208. doi: 10.1182/bloodadvances.2024013427.
2
Ivosidenib: First Global Approval.依维莫司：全球首次获批。
Drugs. 2018 Sep;78(14):1509-1516. doi: 10.1007/s40265-018-0978-3.
3
Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.ivosidenib 治疗异柠檬酸脱氢酶-1 突变型胆管癌。
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):475-481. doi: 10.1080/17474124.2021.1915765. Epub 2021 May 18.
4
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.ivosidenib 治疗 IDH1 突变复发/难治性骨髓增生异常综合征患者的最终 1 期亚组研究结果。
Blood Adv. 2024 Aug 13;8(15):4209-4220. doi: 10.1182/bloodadvances.2023012302.
5
FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.美国食品和药物管理局批准概要：ivosidenib 用于携带异柠檬酸脱氢酶-1 突变的复发性或难治性急性髓系白血病。
Clin Cancer Res. 2019 Jun 1;25(11):3205-3209. doi: 10.1158/1078-0432.CCR-18-3749. Epub 2019 Jan 28.
6
New therapeutics for myelodysplastic syndromes.骨髓增生异常综合征的新疗法。
Leuk Res. 2012 Dec;36(12):1470-4. doi: 10.1016/j.leukres.2012.08.010. Epub 2012 Sep 7.
7
Clinical development of IDH1 inhibitors for cancer therapy.IDH1 抑制剂在癌症治疗中的临床开发。
Cancer Treat Rev. 2022 Feb;103:102334. doi: 10.1016/j.ctrv.2021.102334. Epub 2021 Dec 28.
8
Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.ivosidenib 可显著降低急性髓系白血病和骨髓增生异常综合征患者的唑类药物水平。
Cancer. 2024 Jun 1;130(11):1964-1971. doi: 10.1002/cncr.35251. Epub 2024 Feb 10.
9
A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS.异柠檬酸脱氢酶抑制剂在成年 AML 和 MDS 患者治疗中的研究进展。
Expert Rev Hematol. 2024 Nov;17(11):755-767. doi: 10.1080/17474086.2024.2422554. Epub 2024 Nov 7.
10
Pharmacokinetics/pharmacodynamics of ivosidenib in advanced IDH1-mutant cholangiocarcinoma: findings from the phase III ClarIDHy study.艾伏尼布在晚期异柠檬酸脱氢酶1（IDH1）突变型胆管癌中的药代动力学/药效学：III期ClarIDHy研究结果
Cancer Chemother Pharmacol. 2024 May;93(5):471-479. doi: 10.1007/s00280-023-04633-5. Epub 2024 Jan 27.
本文引用的文献
1
Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.ivosidenib 治疗 IDH1 突变复发/难治性骨髓增生异常综合征患者的最终 1 期亚组研究结果。
Blood Adv. 2024 Aug 13;8(15):4209-4220. doi: 10.1182/bloodadvances.2023012302.
2
Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia.VIALE-A 研究的长期随访：不适合化疗的初治急性髓系白血病患者中应用维奈克拉联合阿扎胞苷。
Am J Hematol. 2024 Apr;99(4):615-624. doi: 10.1002/ajh.27246. Epub 2024 Feb 11.
3
Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.ivosidenib 可显著降低急性髓系白血病和骨髓增生异常综合征患者的唑类药物水平。
Cancer. 2024 Jun 1;130(11):1964-1971. doi: 10.1002/cncr.35251. Epub 2024 Feb 10.
4
Ivosidenib and Azacitidine in -Mutated Acute Myeloid Leukemia.ivosidenib 和阿扎胞苷治疗 - 突变型急性髓系白血病。
N Engl J Med. 2022 Apr 21;386(16):1519-1531. doi: 10.1056/NEJMoa2117344.
5
Impact of Venetoclax and Azacitidine in Treatment-Naïve Patients with Acute Myeloid Leukemia and IDH1/2 Mutations. Venetoclax 和阿扎胞苷在初治伴 IDH1/2 突变的急性髓系白血病患者中的疗效。
Clin Cancer Res. 2022 Jul 1;28(13):2753-2761. doi: 10.1158/1078-0432.CCR-21-3467.
6
Current challenges and unmet medical needs in myelodysplastic syndromes.骨髓增生异常综合征的当前挑战和未满足的医疗需求。
Leukemia. 2021 Aug;35(8):2182-2198. doi: 10.1038/s41375-021-01265-7. Epub 2021 May 28.
7
Management of patients with higher-risk myelodysplastic syndromes after failure of hypomethylating agents: What is on the horizon?低甲基化药物治疗失败后高危骨髓增生异常综合征患者的管理：未来有何进展？
Best Pract Res Clin Haematol. 2021 Mar;34(1):101245. doi: 10.1016/j.beha.2021.101245. Epub 2021 Jan 12.
8
Current and emerging strategies for management of myelodysplastic syndromes.当前和新兴的骨髓增生异常综合征治疗策略。
Blood Rev. 2021 Jul;48:100791. doi: 10.1016/j.blre.2020.100791. Epub 2020 Dec 27.
9
IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.异柠檬酸脱氢酶1（IDH1）突变是骨髓增生异常综合征患者独立的不良预后指标。
Acta Haematol. 2017;138(3):143-151. doi: 10.1159/000479546. Epub 2017 Sep 6.
10
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients.IDH1 与 IDH2 突变在骨髓增生异常综合征中的预后差异：梅奥诊所 277 例患者研究。
Leukemia. 2012 Jan;26(1):101-5. doi: 10.1038/leu.2011.298. Epub 2011 Oct 28.
Zotero 插件